Thank you! I also heard about this on Peter Attia's podcast and was all set to buy one of Pendulum's supplements until a few red flags were raised. Now I'm glad I didn't!
Thank you for clarifying this. I heard about this on Peter Attia’s podcast and wondered what the clinical impact was for the price patients have to pay out of pocket for something that may not provide much benefit.
A sequential approach to controlling type 1 error is adequate. In fact, most clinical trials with clinical approvable endpoints use it on their statistical analysis plan. In short, you are saying that you will test your first endpoint, only if that is statistical significant will you move to your ranked secondary endpoint, and so forth. If the tested endpoint is not s.s. you do not test the other endpoints.
Fantastic article. Thank you for your elucidating thoughts on the "study" and reminder that a double-blind, randomized study still needs interpretation especially when a product is being sold (pushed).
Thank you! I also heard about this on Peter Attia's podcast and was all set to buy one of Pendulum's supplements until a few red flags were raised. Now I'm glad I didn't!
Thank you for clarifying this. I heard about this on Peter Attia’s podcast and wondered what the clinical impact was for the price patients have to pay out of pocket for something that may not provide much benefit.
A sequential approach to controlling type 1 error is adequate. In fact, most clinical trials with clinical approvable endpoints use it on their statistical analysis plan. In short, you are saying that you will test your first endpoint, only if that is statistical significant will you move to your ranked secondary endpoint, and so forth. If the tested endpoint is not s.s. you do not test the other endpoints.
Thank you. 👍
Thanks a LOT for the prudent analysis!
Fantastic article. Thank you for your elucidating thoughts on the "study" and reminder that a double-blind, randomized study still needs interpretation especially when a product is being sold (pushed).
Doc, why did you leave X?